MARKET

DRRX

DRRX

DURECT
NASDAQ
1.340
+0.020
+1.52%
After Hours: 1.290 -0.05 -3.73% 17:44 11/01 EDT
OPEN
1.300
PREV CLOSE
1.320
HIGH
1.380
LOW
1.300
VOLUME
51.17K
TURNOVER
--
52 WEEK HIGH
3.140
52 WEEK LOW
0.4703
MARKET CAP
41.59M
P/E (TTM)
-2.5364
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DRRX last week (1021-1025)?
Weekly Report · 5d ago
Weekly Report: what happened at DRRX last week (1014-1018)?
Weekly Report · 10/21 12:05
Weekly Report: what happened at DRRX last week (1007-1011)?
Weekly Report · 10/14 12:45
Weekly Report: what happened at DRRX last week (0930-1004)?
Weekly Report · 10/07 12:31
Weekly Report: what happened at DRRX last week (0923-0927)?
Weekly Report · 09/30 12:21
Analysts Are Bullish on These Healthcare Stocks: Aytu BioScience (AYTU), Inventiva (IVA)
TipRanks · 09/29 08:10
Durect Corp Annual Meeting Decisions and Shareholder Votes
TipRanks · 09/26 21:00
Durect agreement on larsucosterol trial ‘a major positive,’ says Northland
TipRanks · 09/26 13:00
More
About DRRX
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.

Webull offers DURECT Corp stock information, including NASDAQ: DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.